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Abstract
Background: Heparin/heparan sulfate (HS) proteoglycans are found in the extracellular matrix
(ECM) and on the cell surface. A considerable body of evidence has established that heparin and
heparan sulfate proteoglycans (HSPGs) interact with numerous protein ligands including fibroblast
growth factors, vascular endothelial growth factor (VEGF), cytokines, and chemokines. These
interactions are highly dependent upon the pattern of sulfation modifications within the
glycosaminoglycan chains. We previously cloned a cDNA encoding a novel human endosulfatase,
HSulf-2, which removes 6-O-sulfate groups on glucosamine from subregions of intact heparin.
Here, we have employed both recombinant HSulf-2 and the native enzyme from conditioned
medium of the MCF-7-breast carcinoma cell line. To determine whether HSulf-2 modulates the
interactions between heparin-binding factors and heparin, we developed an ELISA, in which soluble
factors were allowed to bind to immobilized heparin.
Results: Our results show that the binding of VEGF, FGF-1, and certain chemokines (SDF-1 and
SLC) to immobilized heparin was abolished or greatly diminished by pre-treating the heparin with
HSulf-2. Furthermore, HSulf-2 released these soluble proteins from their association with heparin.
Native Sulf-2 from MCF-7 cells reproduced all of these activities.
Conclusion: Our results validate Sulf-2 as a new tool for deciphering the sulfation requirements
in the interaction of protein ligands with heparin/HSPGs and expand the range of potential
biological activities of this enzyme.
Background
Heparan sulfate proteoglycans (HSPGs) abundantly exist
in the ECM and on the cell surface of most cells [1,2]. They
are composed of a restricted set of core proteins to which
one or more glycosaminoglycan chains (GAG) are cova-
lently attached. It is established that HSPGs are involved
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in a wide range of biological functions through their abil-
ity to bind to and modify the activities of a diverse reper-
toire of ligands including growth factors, morphogens,
cytokines, chemokines, proteases, lipases, matrix pro-
teins, and cell adhesion molecules [3-6]. Heparan sulfate
(HS) chains and heparins (chemical analogues of these
chains) consist of repeating disaccharide units of glu-
curonic/iduronic acid and glucosamine that are subject to
a complex set of modifications involving deacetylation,
epimerization, and sulfation. Four different sites of sulfa-
tion are found in heparin/HS: the N-, 3-O, and 6-O posi-
tions of glucosamine and the 2-O position of the iduronic
acid residue. Heparin is highly-sulfated throughout the
polymer chain whereas in HS these modifications are con-
centrated mainly in the S-domains, which consist of con-
tiguous clusters of N-sulfated disaccharide units variably
sulfated at the other positions [7-9]. Interspersed with the
S domains are regions with low (transition zones) or zero
sulfation; however, the transition zones contain a consid-
erable fraction of the 6-O-sulfates in HS [10]. The ligand
binding activities of HSPG/heparin depend on patterns of
sulfation along the chains [2].
HS chains are dynamically regulated in development and
during tumor progression [11,12]. Since these changes are
central to the ligand binding properties of HSPGs, there is
considerable interest in mechanisms that generate diver-
sity of the chains. One such mechanism is through regu-
lated expression of enzymes involved in the biosynthesis
of heparan sulfate, for example, the sulfotransferases that
modify HS chains [13]. Another potential mechanism is
through the action of extracellular endosulfatases that
remove specific sulfation modifications from intact GAG
chains. The first enzyme identified in this category was
QSulf-1, which was discovered in quail embryo [14].
Stimulated by this work, we cloned cDNAs encoding Sulf-
1 and a new member of the family, Sulf-2, in mouse and
human [15]. We showed that both Sulf-1 and Sulf-2 are
secreted into conditioned medium when they are
expressed in Chinese hamster ovary (CHO) cells. Both
possess endoglucosamine-6-sulfatase activity against
intact heparin with an optimum at neutral pH. The
enzymes liberate sulfate groups from the C-6 position of
glucosamine residues on trisulfated -IdoA(2-OSO3)-
GlcNSO3(6-OSO3)- disaccharide units of heparin. A simi-
lar activity for QSulf-1 has now been confirmed on HS
chains [16,17]. This trisulfated disaccharide structure
occurs within the S-domains and is known to be a key ele-
ment in many of the protein ligand interactions of
heparin and HS (see below).
The transcripts corresponding to QSulf-1 and its rat ortho-
logue (RFP-Sulf-1) demonstrate complex spatiotemporal
regulation during embryonic development [14,18] and
QSulf-1 plays an essential role in Wnt-dependent differen-
tiation of somites into muscle in quail [14]. In addition,
in vitro assays have demonstrated that QSulf-1 promotes
both Wnt [14] and bone morphogenetic protein [17] sig-
naling via its sulfatase activity. Less is known about the
distribution and function of the Sulfs in adult tissues.
However, some interesting correlations have been
revealed in tumors. Lai and colleagues have reported
downregulation of Sulf-1 transcripts in human ovarian
cancer and a subset of hepatocellular carcinomas [19-21].
These workers and others have stressed the potential role
of the enzyme in down-modulating certain signaling
pathways involved in cell proliferation, since over-expres-
sion of Sulf-1 reduces signaling by FGF-2, HB-EGF, or
HGF [19-22]. In striking contrast to the results in ovarian
cancer, increased levels of SULF1 or SULF2 transcripts are
observed in other human cancers including breast and
pancreatic carcinomas [23-25]. Upregulation of Sulf-2 at
both the transcript and protein levels has been established
in two mouse models of mammary carcinoma [25]. Fur-
thermore, cultured human breast carcinoma cells release
enzymatically active Sulf-2 into conditioned medium. The
upregulation of Sulf-2 raises the possibility that it may be
involved in promoting tumor progression [24,25].
Indeed, we have shown that Sulf-2 has pro-angiogenic
activity, a relevant function for contributing to tumorigen-
esis [25].
Even before the discovery of the Sulfs, the glucosamine-6-
sulfate modification of HS was the focus of considerable
interest. Thus, it has been shown that suppressing the
expression of heparan sulfate 6-O-sulfotransferases via
gene silencing strategies has pronounced developmental
consequences in both Drosophila and Zebrafish develop-
ment [26,27]. Secondly, binding studies with heparin/HS
fragments and chemically modified heparins point to an
essential contribution of the glucosamine-6-sulfate modi-
fication to their interaction with various protein ligands,
including FGF-1 [28], FGF-10 [29], PDGF [30], VEFG
[31], hepatocyte growth factor [32], lipoprotein lipase
[33], herpes simplex glycoprotein C [34], noggin [17],
and L- and P-selectin [35]. Here, we have taken advantage
of recombinant Sulf-2 generated in 293 cells and of native
Sulf-2 obtained from conditioned medium of a breast car-
cinoma cell line to explore the range of activities for this
enzyme. We have established an ELISA to examine the
effects of Sulf-2 from these two sources on the interaction
of several growth factors and chemokines with immobi-
lized heparin/HS. We found that pre-treatment of heparin
with Sulf-2 significantly reduced its reactivity with certain
ligands but not others ("pre-binding effect") and the
enzyme also dissociated heparin-ligand complexes
("post-binding effect") raising the possibility that it may
be involved in mobilizing HS-bound ligands in the ECM
and basement membranes.BMC Biochemistry 2006, 7:2 http://www.biomedcentral.com/1471-2091/7/2
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Expression and characterization of a recombinant HSulf-2 Figure 1
Expression and characterization of a recombinant HSulf-2. (A) Domains in HSulf-2 are schematically presented. Posi-
tions of peptides that are used to develop polyclonal antibodies are shown. A recombinant protein with a N-terminal FLAG-tag 
(F) (rHSulf-2) and an enzymatically inactivated protein (r∆CCHSulf-2) were designed and produced as described [25]. (B) Puri-
fied rHSulf-2 and r∆CCHSulf-2 produced in 293 cells were blotted with H2.3 anti-HSulf-2 antibody. A 72-kDa and a 74 kDa 
band were detected, respectively. rHSulf-2 was also blotted with a FLAG antibody. (C) Endoglucosamine-6-sulfatase activity of 
rHSulf-2 was measured as a function of enzyme concentration (left panel, 4 h incubation time) and reaction time (right 
panel, 240 ng of rHSulf-2) as described in Methods. rHSulf-2 liberated sulfate groups on C-6 position of glucosamine residues 
within trisulfated disaccharide units in heparin.
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Sulf-2 effects on pre- and post-binding assays for VEFG and FGF-2 Figure 2
Sulf-2 effects on pre- and post-binding assays for VEFG and FGF-2. (A) Solid phase binding assays to measure "pre-
binding effect" and "post-binding effect" are schematically shown. HSulf-2 was incubated with immobilized heparin before or 
after adding heparin-binding factors. Specific primary antibodies quantified the amount of factor bound to immobilized heparin. 
(B) Binding of ligand (VEGF165, FGF-2 or FGF-1) to immobilized heparin-BSA as a function of ligand concentration with or with-
out Sulf-2 treatment of heparin-BSA. ∆ denotes binding of protein to untreated heparin-BSA and ●  denotes binding of VEGF, 
FGF-2 or FGF-1 to rHSulf-2 treated heparin-BSA in pre-binding assay. (C) "Pre-binding effect" of rHSulf-2 (● ) or r∆CCHSulf-2 
(❍ ) on ligand binding (VEFG or FGF-2) to heparin-BSA as a function of enzyme concentration. (D) "Post-binding effect" of 
rHSulf-2 (● ) or r∆CCHSulf-2 (❍ ) on ligand binding (VEFG or FGF-2) to heparin-BSA as a function of enzyme concentration. 
All the results shown are representative of two independent experiments.
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Results
Effect of recombinant HSulf-2 on the binding of VEGF165, 
FGF-1 and FGF-2 to heparin
We wanted to know if Sulf-2, as a 6-O endosulfatase,
could modulate the interaction of known heparin-bind-
ing growth factors to heparin. We prepared and purified
amino-terminal FLAG-tagged HSulf-2 (rHSulf-2) from
stably transfected kidney 293 cells (Figs. 1A and 1B). The
major rHSulf-2 component detected by the H2.3 antibody
migrated with an apparent molecular weight of 72 kDa.
Immunoblotting of rHSulf-2 with a FLAG antibody
revealed a protein band of the same molecular weight
(Fig. 1B). We conclude that the 72 kDa component repre-
sents an N-terminal subunit with a C-terminal truncation.
It should be noted that there are several potential furin
cleavage sites that are C-terminal to the position of the
peptide immunogen (aa 484–504) [15]. It is not known
at present whether protein processing is necessary for
enzymatic activity against heparan sulfate substrates. We
also prepared an enzymatically-inactive mutant of HSulf-
2 [15] in which two essential cysteines were mutated to
alanines (r∆CCHSulf-2). As we had previously shown for
CHO cell-produced material [15], rHSulf-2 exhibited
endosulfatase activity against heparin in a concentration-
and time- dependent manner (Figs. 1C and 1D). The assay
employs HPLC to examine to the disaccharide composi-
tion of treated and untreated heparin (see Methods). After
24 h of enzyme treatment, 80% of the trisulfated disac-
charides were converted to the disaccharide products. The
mutant protein was inactive in this assay (data not
shown). We next developed solid phase ELISAs to meas-
ure the binding of protein ligands to immobilized
heparin-BSA. Antibodies directed to the ligands were used
for detection. For "pre-binding" effects, we first treated
heparin-BSA with rHSulf-2 and then tested for its ability
to support ligand binding (Fig. 2A). For "post-binding"
effects, we determined the ability of rHSulf-2 to release the
ligand from a preformed complex with heparin-BSA (Fig.
2A).
We initially focused our attention on three growth factors:
VEGF165, FGF-1 and FGF-2. Sulfate groups in heparin/HS,
including glucosamine-6-sulfates, are required for the
interaction of VEGF165  and FGF-1 with heparin/HS
[28,31,36]. In contrast, FGF-2 binding to heparin/HS
depends on N-sulfation and iduronate-2-sulfation but not
on 6-O-sulfation [28,36,37]. We observed saturable bind-
ing of VEGF165, FGF-1 and FGF-2 to heparin-BSA (Figs. 2B
and 4B). We estimated Kd's for these interactions and the
binding of three chemokines (CXCL12, CCL21, and
CXCL8) to heparin-BSA (Table 1). Negligible binding was
seen when the wells were coated with BSA alone (data not
shown). As a positive control to eliminate heparin-
dependent binding, we pre-digested heparin-BSA with a
mixture of heparinases (0.2 mU of heparinase I, 0.1 mU
of heparinase II and 0.04 mU of heparinase III) for 4 h
and found that this digestion reduced the binding of
VEGF by >92%. Treatment of heparin with rHSulf-2
reduced the binding of varying concentrations of VEGF to
heparin-BSA almost to background levels (Fig. 2B).
rHSulf-2 treatment diminished the binding of FGF-1 by
>60%. In contrast, rHSulf-2 had only a negligible effect on
the binding of FGF-2 to heparin (Fig. 2B). To determine
the efficacy of the enzyme, we fixed the concentration of
ligand at approximately its Kd and tested varying concen-
trations of rHSulf-2 or the inactive mutant, r∆CCHSulf-2.
For FGF-2, only minimal effects of rHSulf-2 were seen up
to 100 ng of the enzyme, whether tested in the pre-bind-
ing (Fig. 2C) or post-binding assay (Fig. 2D). In contrast,
treatment of heparin-BSA with 50 ng or more of rHSulf-2
substantially reduced its binding to VEGF in a dose-
dependent manner (Fig. 2C), whereas the mutant enzyme
was largely inactive. In the post-binding assay, rHSulf-2
was also efficacious in releasing VEGF from preformed
complexes with heparin-BSA (Fig. 2D, Table 2). The slight
inhibitory effects of r∆CCHSulf-2 (Figs. 2C and 2D) in
both the pre-binding and post-binding assays may be
attributable to a competing heparin-binding activity of
Sulf-2 protein due to its highly basic hydrophilic domain
[15].
Effects of HSulf-2 on chemokine binding to heparin-BSA
Chemokines are also heparin/HS-binding proteins [6].
However, limited information is available about the spe-
cific sulfation requirements for these interactions. We
therefore took advantage of rHSulf-2 to determine the
contributions of glucosamine-6-sulfation to these interac-
tions. rHSulf-2 was very effective in reducing the interac-
tion of SDF-1 (CXCL12) with heparin-BSA in both pre-
binding and post-binding assays (Fig. 3A and 3B, Table 2).
In contrast, rHSulf-2 had only partial inhibitory effects on
the binding of SLC (CCL21) to heparin-BSA (Fig. 3A). IL-
Table 1: Estimated dissociation constants for the interaction of 
ligands with immobilized heparin-BSA and heparan sulfate (HS)-
BSA
Ligand Kd value (nM)
Heparin-BSA HS-BSA
VEGF 12.5 >200
FGF-1 9.2 26
FGF-2 8.6 N.D.
CXCL12 (SDF-1) 75 N.D.
CCL21 (SLC) 5.5 N.D.
CXCL8 (IL8) >180 N.D.
Each Kd value was estimated from the concentration of ligand needed 
for half-maximal saturation. In the cases of IL-8 binding to heparin-
BSA and VEGF binding to HS-BSA, saturation was not observed at the 
highest concentration tested.
N.D., not determined.BMC Biochemistry 2006, 7:2 http://www.biomedcentral.com/1471-2091/7/2
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8 (CXCL8) bound less well to heparin-BSA, but rHSulf-2
treatment still attenuated the interaction (Fig. 3A).
Analysis of the activity of native HSulf-2 in MCF-7 
conditioned medium
SULF2 transcripts are upregulated in breast, central nerv-
ous system and colon carcinomas [24,25]. Moreover, tran-
scripts are detected in some cultured human breast
carcinoma cell lines and the mRNA-positive cells release
Sulf-2 protein in their conditioned medium [25]. Sulf-2
expression is highest in the conditioned of MCF-7 cells
and we have demonstrated that the secreted protein has
associated arylsulfatase activity using 4-methylumbellif-
eryl sulfate as the substrate [25]. As shown in Fig. 4A, the
CM from these cells exhibited concentration- and time-
dependent endoglucosamine-6-sulfatase activity against
heparin. In pilot experiments, the CM also showed activ-
ity against bovine intestinal heparan sulfate (HS) produc-
ing a substantial reduction in the amount of the
trisulfated disaccharide with a corresponding increase in
the amount of the disulfated disaccharide product (data
not shown). Using CM as a source of the native enzyme,
we analyzed the "pre-binding" and "post-binding" effects
on the binding of VEGF or FGF-2 to heparin. Consistent
with the rHSulf-2 findings, pretreatment of heparin-BSA
with a fixed concentration of MCF-7 CM strongly reduced
the subsequent binding of VEGF165 or FGF-1 but had no
effect on the binding of FGF-2 (Fig. 4B). In a dose-depend-
ent manner, CM prevented (Fig. 4C) and reversed (Fig.
4D) the interaction of VEGF165 or FGF-1 with heparin-
BSA. Similar effects were observed with SDF-1 (data not
shown). In contrast, the same range of CM concentrations
had no appreciable effect on the binding of FGF-2 to
heparin-BSA in either the pre-binding or post-binding
assays (Figs. 4C and 4D). To confirm that the reductions
in heparin binding were, in fact, due to Sulf-2, we
employed anti-HSulf-2 antibodies [25] for immunodeple-
tion of Sulf-2 from MCF CM. Pre-clearing was carried out
by incubating CM with protein A-Sepharose complexed to
a mixture of two specific antibodies and then centrifuging
the mixture. As shown by Western blotting, the specific
antibodies removed the majority of HSulf-2 protein from
the CM, whereas control IgG removed only a relatively
small amount of the protein (Fig. 4E). In parallel with the
depletion of HSulf-2 protein, the "pre-binding" activity of
the precleared CM, measured with respect to VEGF165
binding, was greatly diminished as compared to that of
the control IgG-treated CM (Fig. 4F).
Effects of HSulf-2 on heparan sulfate interactions
Heparin is a structural analogue of the S-domains of
heparan sulfate. We wanted to determine whether the
effects of Sulf-2 on heparin interactions would be
repeated with bona fide heparan sulfate. For this purpose,
we conjugated BSA with heparan sulfate chains (HS-BSA)
that were isolated from porcine intestinal mucosa. FGF-1
bound to HS-BSA, although with a 3-fold lower affinity
than to heparin-BSA (Fig. 5, Table 1). This binding was
abolished by pre-digestion of the HS chains with hepari-
nases. Pretreatment of the HS-BSA with MCF-7 CM or
rHSulf-2 substantially diminished FGF-1 binding (55–
70% reduction), whereas r∆CCHSulf-2 did not exert this
effect (Fig. 5).
Discussion
The Sulfs are 6-O endosulfatases that act on the trisulfated
disaccharide unit (-IdoA(2-OSO3)-GlcNSO3(6-OSO3)-)
which is the most common unit in heparin but is largely
confined to the S-domains of HS [15-17]. As the heteroge-
neous pattern of sulfation within S domains is known to
dictate the binding specificity of many proteins for
heparin/HS [7], the Sulfs could potentially regulate those
interactions with a dependence on the presence of trisul-
fated disaccharides within the binding motif. Here, we
have employed Sulf-2 as a tool to explore the binding
requirements of several proteins, some of which had been
previously characterized and others whose binding
requirements were largely unknown. Previous work has
shown that QSulf-1 treatment of soluble recombinant
form of an HSPG (Glypican-1) reduced its ability to bind
a Wnt ligand [16]. Also, the interaction of Noggin with
cell surface HSPGs was diminished by the overexpression
of QSulf-1 in the cells [17]. In the present study we have
taken advantage of two sources of soluble HSulf-2: recom-
binant enzyme purified from stably transfected 293 cells
and a natural form of the enzyme in CM of a human
breast carcinoma cell line (MCF-7). It should be noted
that we have not been able to obtain expression of high
level of Sulf-1 in CM of transfected 293 cells, nor have we
yet identified a soluble form of this enzyme from a native
source.
Table 2: Comparison of rHSulf-2 requirements for mobilization 
of heparin-bound ligands
Ligand Concentration required for 50% 
release of heparin-bound ligand
rHSulf-2 (µg/mL)
VEGF 0.34
FGF-1 0.36
FGF-2 >4.0
CXCL12 (SDF-1) 0.44
CCL21 (SLC) 3.1
CXCL8 (IL-8) 3.4
CXCL10 (IP-10)a 2.0
a Kd for heparin-BSA was 62 nM. The fixed concentration of ligand 
tested in the assay was 50 nM.BMC Biochemistry 2006, 7:2 http://www.biomedcentral.com/1471-2091/7/2
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Sulf-2 effects on pre- and post-binding assays for chemokines Figure 3
Sulf-2 effects on pre- and post-binding assays for chemokines. (A) Binding of CXCL12 (SDF-1), CCL21 (SLC) and 
CXCL8 (IL8) to immobilized heparin-BSA as a function of ligand concentration with or without Sulf-2 treatment of heparin-
BSA. ∆ denotes binding of chemokines to untreated heparin-BSA and ●  denotes binding of chemokines to rHSulf-2 treated 
heparin-BSA in pre-binding assay. (B) "Pre-binding effect" (left panel) and "post-binding" effect (right panel) of rHSulf-2 (● ) 
or r∆CCHSulf-2 (❍ ) on ligand binding (CXCL12) to heparin-BSA as a function of enzyme concentration. Values represent the 
means ± S.D. of triplicate determinations in the binding assays for CXCL8 and CXCL12. Statistical analysis was carried out 
using Student's t test. **, p < 0.01; ***, p < 0.001. The other data are representative of two independent trials.
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Sulf-2 activity in MCF-7 CM Figure 4
Sulf-2 activity in MCF-7 CM. (A) Endosulfatase activity of CM on heparin as a function of CM volume (left panel, 4 h incu-
bation time) and reaction time (right panel, 10 µl of CM). (B) Binding of ligand (VEGF165, FGF-2 or FGF-1) to immobilized 
heparin-BSA as a function of ligand concentration with or without CM treatment of heparin-BSA. ∆ denotes binding of ligand 
to untreated heparin-BSA and ●  denotes binding of ligand to CM treated heparin-BSA in pre-binding assay. Means of triplicate 
determinations ± S.D. are shown. In those cases where the error bars are not apparent, the S.D. values are smaller than the 
symbols. (C) "Pre-binding effect" of CM on ligand binding (VEGF165, black triangles; FGF-2, black squares; FGF-1, open dia-
monds) as a function of CM volume. These results are representative of two independent experiments (D). "Post-binding 
effect" of CM on ligand binding (VEGF165, black triangles; FGF-2, black squares; FGF-1, open diamonds) as a function of CM vol-
ume. Means of triplicate determinations are shown. S.D. values for FGF-1 are indicated. The S.D. values for VEGF and FGF-2 
are smaller than the symbols. (E) Immuno-depletion of HSulf-2 protein by specific antibodies. MCF-7 CM was precleared with 
Sulf-2 antibodies (H2.1 and H2.3) or control IgG conjugated to beads and then blotted for Sulf-2 protein (H2.3). Arrows 
denote specific bands detected in the untreated MCF-7 CM (~240, 135 and 72 kDa). The ~50 kDa bands indicated by the 
asterisk are derived from the IgG used for the precipitation (F). Immuno-depletion of HSulf-2 activity by specific antibodies. 
The precleared CMs in E were tested in a pre-binding assay for effects on VEGF binding to heparin-BSA. The partial depletion 
of activity by control IgG reflects the tendency of Sulf-2 to bind nonspecifically to Sepharose beads (not shown). Means and 
S.D. values are shown for triplicate determinations. Statistical analysis was carried out using Student's t test. **, p < 0.01.
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We have previously shown that native Sulf-2 in MCF-7
CM has arylsulfatase activity [25]. In the present study, we
have used HPLC to demonstrate that MCF-7 CM possesses
endosulfatase activity against intact heparin. This result
has also been established by an alternative approach using
mass spectroscopy [38]. Employing an ELISA based on
binding of protein ligands to heparin-BSA conjugate, we
found that rHSulf-2 strongly modulated the binding of
VEGF165, FGF-1, and SDF-1 to porcine intestinal heparin.
In the case of FGF-1, the inhibitory effect of Sulf-2 was
also demonstrated for heparan sulfate chains as well,
using a HS-BSA conjugate. All of the effects obtained with
the recombinant enzyme were observed for MCF-7 CM,
and we confirmed that the activity in the CM was due to
Sulf-2. The porcine intestinal heparin used in this study
contained 70% trisulfated disaccharides, 18% disulfated
disaccharides, 7% monosulfated disaccharides and 5%
unsulfated disaccharides (data not shown). Based on our
previous work [15] and the present study, we estimate that
about 80% of the total trisulfated disaccharides in
heparin-BSA was converted into disulfated disaccharides
by Sulf-2. Thus, only about 22% of the overall sulfate moi-
eties were removed by the enzyme treatment, arguing
against the possibility that the reduced binding of selec-
tive protein ligands to treated heparin was due to a reduc-
tion in overall charge. As heparan sulfates have limited S-
domains [7], Sulf-2 would be predicted to have an even
smaller effect on the global sulfation of HSPGs. A further
indication of the selectivity of Sulf-2 is that there is no
relationship between the estimated Kd for binding of each
ligand to heparin-BSA (Table 1) and the susceptibility of
the interaction to the enzyme (Table 2).
The Sulf-2 effects on FGF-1 binding were anticipated
based on a number of correlative studies [28,39], which
have implicated the trisulfated disaccharide motif as a
binding element in HS chains. Our VEGF165 results are
compatible with a previous study in which chemical 6-O-
desulfation of heparin strongly weakened its ability to
interact with VEGF165 [31]. However, our findings provide
the first direct evidence that 6-O-sulfation of heparin
within the context of the trisulfated disaccharide motif is
essential for the interaction. The majority of VEGF iso-
forms are able to bind to heparin/HS [40], and it is antic-
ipated that our results will generalize to these other forms
as well. With respect to SDF-1, it has long been known
that this highly basic chemokine binds relatively strongly
to heparin [41], but the fine specificity of the interaction
has not previously been explored. SLC and IL-8 showed a
partial sensitivity to the desulfation effects of Sulf-2 on
heparin. This partial susceptibility implies that the 6-O-
sulfation of the trisulfated disaccharide can contribute but
is not absolutely required for a measurable binding inter-
action with heparin. One important avenue for future
investigation is based on our observation that Sulf-2
strongly modulated the interactions of two chemokines
(SDF-1 and SLC) with heparin. SDF-1 has been implicated
in a diverse range of processes such as lymphocyte chem-
otaxis, stem cell homing and retention, tissue repair, ang-
iogenesis, and organ-specific metastasis [42], whereas SLC
is important in lymphoid organ homeostasis and inflam-
mation [43]. Thus, Sulf-2 though effects on the ECM-asso-
ciation of chemokines could have important roles in a
number of normal and pathophysiologic processes.
HSulf-1 with an apparently indistinguishable enzymatic
activity [15] may exert similar effects on HSPG-bound
growth factors and chemokines.
It is well established that one function of heparan sulfate
proteoglycans in the ECM and basement membranes is to
sequester protein ligands away from signal transduction
receptors [44,45]. A known mechanism to regulate the
mobilization of such factors is through the action of
heparanase, an endo-ß-D-glucuronidase that degrades
heparan sulfate chains into relatively large fragments [46].
This enzyme is present in a number of normal cell types
(e.g., leukocytes, platelets, cytotrophoblasts) and is upreg-
ulated in several cancers. Expression of heparanase in a
number of settings elicits angiogenesis, apparently
through the release of HSPG-bound angiogenic factors
[44,47]. Our finding that Sulf-2 can reverse the associa-
tion between heparin and angiogenic factors (e.g., VEGF)
suggests the possibility of functional parallels between
these two enzymes. Sulf-2 may mobilize VEGF or other
The effect of Sulf-2 on FGF-1 binding to heparan sulfate-BSA Figure 5
The effect of Sulf-2 on FGF-1 binding to heparan sul-
fate-BSA. FGF-1 binding to heparan sulfate-BSA was meas-
ured after the following treatments of the conjugate: no 
treatment; MCF-7 CM; rHSulf-2; r∆CCHSulf-2; or a mixture 
of heparinases. Values represent the means ± S.D. of three 
separate determinations. Statistical analysis was carried out 
using Student's t test. **, p < 0.01.
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angiogenic factors sequestered in the ECM and increase
their bioavailability to endothelial cells that express the
appropriate signaling receptors. The ability of rHSulf-2 to
promote angiogenesis in the chick chorioallantoic mem-
brane (CAM) assay is consistent with such a scenario [25].
Thus, the observed upregulation of Sulf-2 in mammary
carcinomas and its secretion from these cells could
directly contribute to tumor angiogenesis and thus tumor
growth. Sulf-2 derived from a cancer cell could also con-
ceivably mobilize HSPG-bound growth factors that then
act back on the cancer cell and thus trigger its own prolif-
eration. The ability of QSulf-1 to promote Wnt signaling
within the cells that express the enzyme provides a plausi-
ble paradigm for this type of autocrine pathway [14,16]. It
should be borne in mind that in the context of some other
signaling pathways (e.g., FGF-2 and HGF), Sulf-2 is likely
to exert a negative effect.
Conclusion
As demonstrated in the present study, Sulf-2 can modu-
late the interaction of a number of important bioactive
proteins with heparin/HS. A major finding of our study is
that Sulf-2 completely disrupts the interaction of certain
factors with heparin. As expected, the factors for which
Sulf-2 strongly blocks binding to heparin in the pre-bind-
ing format are the most susceptible to reversal effects in
the post-binding assays (VEGF, FGF-1, and SDF-1). These
observations indicate that, irrespective of the engagement
of a protein ligand, Sulf-2 has access to the 6-O-sulfate
group of the trisulfated disaccharide units of intact
heparin. Recombinant Sulf-2 provides a valuable tool for
investigating the specific sulfation requirements for
heparin/HS interactions of interest. Furthermore, future
application of the assays described herein will certainly
expand the range of interactions that can be modulated by
Sulf-2 and should enhance our understanding of the
potential functional roles served by this enzyme in situ.
Methods
Materials
The following materials were obtained commercially
from the source indicated. Heparin conjugated with
bovine serum albumin (Heparin-BSA), BSA, heparinases
(I, II and III) were from Sigma (St Louis, Mo., USA);
heparan sulphate (porcine intestinal mucosal) from Orga-
non (Oss, The Netherlands); DEAE-Sephacel from Sigma
(Poole, UK); Phenyl-Sepharose CL-4B from Amersham
Biosciences (Little Chalfont, UK); Protein A Sepharose
beads from RepliGen (Needham, MA); recombinant
human VEGF165, human CXCL12 (SDF-1), anti-human
VEGF antibody (Ab), anti-human FGF-1 Ab, anti-human
FGF-2 Ab, anti-human CXCL12 Ab, anti-CXCL8 Ab and
anti-human CCL21 Ab from R&D Systems. All are poly-
clonal antibodies produced in goats. Recombinant
human FGF-1 (acidic FGF), human FGF-2 (basic FGF),
human CCL21 (SLC) and CXCL8 (IL-8) were from Leinco
Inc. A biotinylated swine anti-goat IgG (H+L) antibody
and a streptavidin conjugated with alkaline phosphatase
were from Caltag. FLAG-tagged versions of HSulf-2 and
the inactive mutant designated ∆CCHSulf-2 were pro-
duced in 293 cells and purified as previously described
[25]. Polyclonal rabbit anti-bodies against HSulf-2 (H2.1
and H2.3) were generated and prepared as previously
described [25].
Heparan sulfate-BSA conjugate
Porcine intestinal mucosal heparan sulfate was coupled,
via its reducing end, to BSA based on the procedure of
Najjam et al. [48]. Briefly, 2 mg of sodium cyanoborohy-
dride was added to a mixture of 50 mg of HS and 2 mg of
BSA in 2 ml of 0.2 M potassium phosphate buffer pH 8.
The mixture was then incubated for 2 days at 37°C. After
dilution to 10 ml with 0.15 M NaCl, 20 mM phosphate,
pH7.4, it was applied to a 5 ml column of DEAE-Sephacel
equilibrated in the same solution. After washing with 0.15
M NaCl solution, followed by buffered 0.4 M NaCl, to
remove reagents and any non-conjugated BSA, the HS-
containing material was then step-eluted with 0.5 ml aliq-
uots of buffered 1.5 M NaCl. HS-containing fractions were
identified by spotting aliquots onto Whatman filter paper
and staining with Azure A. The pooled fractions were
adjusted to 3 M in (NH4)2SO4,  by addition of solid
(NH4)2SO4, and then applied to a 2 ml column of Phenyl-
Sepharose CL-4B equilibrated in 3 M (NH4)2SO4. After
washing with 3 M (NH4)2SO4 to elute free HS, the bound
HS-BSA conjugate was step-eluted with 0.5 ml aliquots of
0.15 M NaCl, 20 mM phosphate pH7.4. Fractions con-
taining conjugated BSA were identified by their absorb-
ance at 280 nm. The final product ran as a diffuse band,
stainable with both Coomassie Blue and Azure A, close to
the top of a 10% polyacrylamide SDS-PAGE gel and with
a higher apparent MW than free BSA. The BSA content of
the conjugate was assessed by absorbance at 280 nm. The
HS content was determined by digestion with a mixture of
heparinases I, II and III, and measurement of the resulting
increase in absorbance at 232 nm. It was estimated that
the average level of conjugation was 1–2 HS chains/BSA
molecule.
Preparation of recombinant Sulf-2 and CM from MCF-7 
cells
FLAG-tagged versions of active Sulf-2 (rHSulf-2) and inac-
tive enzyme (r∆CCHSulf-2) were produced in stably
transfected kidney 293 cells as described previously [25].
The purities of rHSulf-2 and r∆CCHSulf-2 were estimated
to be 90% and 80%, respectively based on Coomassie
blue staining of SDS-PAGE gels. The amount of Sulf-2 pro-
tein was quantified by the BCA assay (Pierce). The
amounts of rHSulf-2 and r∆CCHSulf-2 were equalized by
an ELISA employing an anti-FLAG M2 antibody (Sigma)BMC Biochemistry 2006, 7:2 http://www.biomedcentral.com/1471-2091/7/2
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as the capture reagent and a mix of H2.1 and H2.3 anti-
bodies for detection. The human breast carcinoma cell
line, MCF-7, was grown in RPMI-1640 containing 10%
fetal calf serum in a 150 mm-flask. Cells (80% confluent)
were rinsed with PBS and OptiMEM (Invitrogen) and then
incubated in 25 ml of OptiMEM at 37°C in 5% CO2 for
72 h. The CM was collected and then 100-fold concen-
trated on a Centricon-30. Subsequently, the concentrated
CM was dialyzed into 50 mM HEPES, pH 8.0.
ELISAs for "pre-binding" and "post-binding" effects of 
HSulf-2
The experimental design for these ELISA is schematically
shown in Fig 2A. To immobilize heparin, 100 ng/ml of
heparin-BSA in phosphate-buffered saline (PBS) was
added to the wells (100 µl/well) of a 96-well plate (Immu-
lon 2HB, Dynex Labs). The plate was placed at 4°C over-
night. The wells were washed 3 times with PBS containing
0.1% Tween-20 (PBS-T) and then blocked with 3% BSA
(Sigma) in PBS-T at 25°C for 2 h. To determine the effects
of Sulf-2 on the ligand-binding activities of heparin ("pre-
binding" effects), the wells were washed as above and
then incubated with 100 µl of a reaction mixture contain-
ing 5 µmol of HEPES, pH 7.6, 1 µmol of MgCl2 and
enzyme (rHSulf-2, r∆CCHSulf-2 or MCF-7 CM) at 37°C
for 4 h. In the cases where we carried out dose response
studies with protein ligands, incubation with the enzyme
was overnight. The wells were washed 3 times with PBS-T
and then incubated with 25 µl of heparin-binding factors
(25 nM VEGF, 12.5 nM FGF-2, 12.5 nM FGF-1, and 100
nM CXCL12) in PBS at 25°C for 30 min. The wells were
washed 3 times and incubated with 1 µg/ml of each pri-
mary antibody in 0.1% BSA/PBS (100 µl/well) at 25°C for
1 h. The wells were washed as above and incubated with
1.2 µg/ml of a biotinylated secondary antibody in 0.1%
BSA/PBS (100 µl/well) at 25°C for 30 min. Then, the
wells were washed and incubated with 2 µg/ml of an
alkali phosphatase-conjugated streptavidin in 0.1% BSA/
PBS (100 µl/well) at 25°C for 30 min. Finally, the wells
were incubated with PNPP (Pierce) in cacodylate buffer,
pH 9.2 (100 µl/well) at 25°C for 5 minutes, and then OD
405 nm was read on a microplate reader. For the analysis
of "post-binding" effects (i.e. dissociation of heparin-lig-
and complexes), 25 µl of each heparin-binding factor was
added to plates coated with heparin-BSA after blocking
with 3% BSA. The plates were incubated at 25°C for 30
min to form the heparin-factor complex. The wells were
washed as above and then incubated with 100 µl of the
enzyme reaction mixture as described above. After wash-
ing the wells, the amount of bound factor was determined
with the antibody detection procedures described above.
For the "pre-binding" study of FGF-1 binding to heparan
sulfate-BSA, 1 mg/ml of heparan sulfate-BSA was coated
on a 96-well plate (100 µl/well). Other procedures are the
same as described above for the heparin-BSA assay. Repre-
sentative data are shown from one of 2–3 independent
experiments in all cases.
Western blotting
A purified FLAG-tagged HSulf-2 (10 ng) or concentrated
MCF-7 CM (10 µl) was separated by electrophoresis on a
reducing SDS-7.5% polyacrylamide gel (Bio-Rad), and
blotted onto ProBlott™ membrane (Applied Biosystems,
Foster City, CA). The membrane was blocked with 5%
skim milk/PBS-T for 1 h and then incubated overnight
with an anti-HSulf-2 peptide antibody (see below) at a
concentration of 1 µg/ml in 5% skim milk/PBS-T at 4°C.
The membrane was washed and incubated with horserad-
ish peroxidase-conjugated goat anti-rabbit IgG (Jackson
ImmunoResearch Laboratories Inc, West Grove, PA) (0.2
µg/ml) for 1 h. Bound antibodies were visualized with
SuperSignal West Pico Chemiluminescent reagent
(Pierce).
Immunoprecipitation of HSulf-2 in MCF-7 CM
A mixture of anti-HSulf-2 peptide antibodies, H2.1 (5 µg)
and H2.3 (5 µg) [25], or a rabbit IgG (10 µg), 10 µl of a
50% (v/v) suspension of protein A-Sepharose (IPA-
400HC, RepliGen) and 100 µl of 100-fold concentrated
CM of MCF-7 cells were mixed in a total volume of 1 ml
with 150 mM NaCl and 50 mM Tris-HCl, pH 7.4. The
mixture was rocked overnight at 4°C. The immunocom-
plexes bound to the protein A beads were removed by cen-
trifugation. The "pre-binding" and "post-binding" ELISA
activities remaining in the supernatant were assayed as
described above.
Endoglucosamine-6-sulfatase assay
Endoglucosamine-6-sulfatase activity of rHSulf-2 and
MCF-7 CM was determined by previously established pro-
cedures [15]. The standard reaction mixture contained 5
µmol of HEPES, pH7.8, 1 µmol of MgCl2, 5 µg of porcine
intestinal heparin (Sigma), and a purified FLAG-tagged
HSulf-2 or a 100-fold concentrated MCF-7 CM in a total
volume of 100 µl. The mixture was incubated at 37°C.
The reaction was stopped by heating at 100°C for 2 min.
The heparin was digested into disaccharides by a mix of
heparinase I, heparinase II and heparinase III [15]. The
disaccharides were then analyzed by HPLC on a Partisil-
10 SAX column (Whatman, Fairfield, NJ) [15]. The enzy-
matic activity was defined by calculating the increase in
the moles of unsaturated disulfated disaccharide,
IdoA(2S)-Glc(NS), in the digested heparin.
List of abbreviations used
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Sulf-2, recombinant inactive mutant of human Sulf-2;
SAGE, serial analysis of gene expression; SDF, stromal
cell-derived factor; VEGF, vascular endothelial growth fac-
tor.
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